Thursday 16 October, 2025
Rilmenidine is a centrally-acting antihypertensive drug with binding selectivity to newly described I, imidazoline receptors over G2-adrenoceptors. The drug is…
Read moreposter
Pharmacokinetic and pharmacodynamics of AR-C69931MX a novel P2T antagonist in healthy male and female volunteers.
Thursday 16 October, 2025
Introduction: AR-C69931MX is a potent and selective P2T receptor antagonist acting as an inhibitor of adenosine diphosphate (ADP) induced platelet…
Read moreFluticasone propionate pharmacokinetics in asthma patients when administered alone or in combination to salmeterol.
Thursday 16 October, 2025
Seretide is a combination of Salmeterol (50pg) with Fluticasone propionate (500pg) administered twice daily by inhalation for treatment of asthma….
Read morePopulation PK/PD Modelling of 24h-Ambulatory Blood Pressure Data using NONMEM
Thursday 16 October, 2025
Although approval of novel antihypertensive compounds is still based on manual blood pressure measurements, regulatory authorities ask for 24h-ambulatory blood…
Read morePopulation pharmacokinetics of Navelbine: Model set up from phase I data and Validation of a limiting sampling strategy
Thursday 16 October, 2025
Navelbine (vinorelbine tartrate) is a vinca-alkaloid antimitotic agent which has been marketed since 1989 by Pierre Fabre Laboratory as iv…
Read morePopulation Pharmacodynamic Modelling of Levodopa in Parkinsonian Patients Receiving the COMT Inhibitor Entacapone
Thursday 16 October, 2025
Nineteen parkinsonian patients (11F, 8M), with fluctuations in response were studied in five one-day occasions, each separated by one week,…
Read moreEstimation Of Bioavailability Using A Semi-Simultaneous Design
Thursday 16 October, 2025
The semi-simultaneous design is an alternative to the traditional crossover design in bioavailability studies. The test and reference treatments are…
Read morePopulation Pharmacokinetics-Pharmacodynamics Of A New Specific Bradycardic Agent (S 16257) And Its Metabolite (S 18982) Evaluation Of The Drug/Metabolite Potency Ratio
Thursday 16 October, 2025
S 16257, under development for treatment in myocardial ischaemia, belongs to the new pharmaceutical class of specific bradycardic agents. Its…
Read moreChange In The Analytical Error Function Depending On The Calibration Curve Range: Implications For Pharmacokinetic Parameter Estimation Of Carebastine.
Thursday 16 October, 2025
The error function of a previously validated analytical procedure used as a weighting method in least squares nonlinear regression analysis,…
Read morePopulation Analysis Of Lubeluzole Pharmacokinetics In Healthy Volunteers And Patients With Ischaemic Stroke
Thursday 16 October, 2025
Lubeluzole is a benzotriazole derivative exhibiting anti-hypoxic properties which is currently being developed for the use in ischaemic stroke. Population…
Read more